CVACCureVac N.V.

Nasdaq curevac.com


$ 3.46 $ 0.21 (6.44 %)    

Monday, 24-Jun-2024 15:59:48 EDT
QQQ $ 474.01 $ -6.22 (-1.3 %)
DIA $ 394.05 $ 2.64 (0.67 %)
SPY $ 542.74 $ -1.77 (-0.33 %)
TLT $ 94.32 $ 0.38 (0.4 %)
GLD $ 215.63 $ 0.85 (0.4 %)
$ 3.47
$ 3.37
$ 0.00 x 0
$ 0.00 x 0
$ 3.30 - $ 3.56
$ 2.22 - $ 12.27
903,831
na
777.24M
$ 1.52
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 first-human-death-from-bird-flu-strain-puts-vaccine-stocks-back-on-the-map

Moderna shares are up almost 29% this month; CureVac is up 72% in the past month; and Novavax spiked 317% in the past month.

Core News & Articles

https://globalnews.ca/news/10547712/bird-flu-death-mexico-h5n2/#:~:text=It%20started%20on%20April%2017,to%20complications%20of%...

 elon-musk-breaks-ranks-with-gop-by-praising-genetic-engineering-tech-that-helped-fight-covid-19-digital-medicine-with-incredible-potential

Elon Musk has come off as a flagbearer of the mRNA technology, which is seen holding out a lot of promise by scientists.

 covid-19-patent-dispute-sorted-acuitas-therapeutics-and-curevac-reach-settlement-in-patent-battle

Acuitas Therapeutics settles lawsuit with CureVac over COVID-19 vaccine patents. Legal disputes unfold among biotech giants Pfi...

 leerink-partners-downgrades-curevac-to-market-perform-lowers-price-target-to-4

Leerink Partners analyst Mani Foroohar downgrades CureVac (NASDAQ:CVAC) from Outperform to Market Perform and lowers the pri...

Core News & Articles

https://www.curevac.com/en/curevac-announces-start-of-combined-phase-1-2-study-in-avian-influenza-h5n1-development-in-collabora...